Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2018 · 10-Q
Revenue$545.14M$545.14M+2.1% vs Q3 2017 Net Income$269.30M$269.30M+1,118.6% vs Q3 2017 EPS Diluted$8.89$8.89+1,117.8% vs Q3 2017 Gross Profit$286,700,000−4.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$62,277,000+118.7% Free Cash Flowderived$40,223,000+392.8% Margins · derivedGross margin52.6%−3.4 pt vs Q3 2017
Operating margin6.7%−0.6 pt vs Q3 2017
Net margin49.4%+45.3 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 5, 2018 · 36 d after period end